Impaired activation of Stat1 and c-Jun as a possible defect in macrophages of patients with active tuberculosis.
Studies of patients with active tuberculosis (TB) and infected healthy individuals have shown that interferon (IFN)-gamma is present in sites of Mycobacterium tuberculosis infection in comparable levels. This suggests that there is a deficiency in the macrophage response to IFN-gamma in TB patients. We used recombinant human IFN-gamma to stimulate adherent monocyte-derived macrophages from three groups of people: patients with active tuberculosis (TBP), their healthy household contacts (HHC) and healthy uninfected controls from the community (CC). We then evaluated the ability of the macrophages to inhibit the growth of M. tuberculosis H37Rv as well as their cytokine profile at early in infection (48 h). After IFN-gamma treatment, macrophages of healthy individuals (HHC and CC) controlled M. tuberculosis growth and produced mainly nitric oxide (NO) and interleukin (IL)-12p70, whereas TBP macrophages did not kill M. tuberculosis. Additionally, TBP macrophages produced low levels of NO and IL-12p70 and high levels of tumour necrosis factor (TNF)-alpha and IL-10. Transforming growth factor (TGF)-beta levels were similar among all three groups. M. tuberculosis infection had little effect on the cytokine response after IFN-gamma stimulus, but infection alone induced more IL-10 and TGF-beta in TBP macrophages. There were no differences in Stat1 nuclear translocation and DNA binding between the groups. However, the phosphorylated Stat1 and c-Jun (AP-1) in nuclear protein extracts was diminished in TBP macrophages compared to macrophages of healthy individuals. These results indicate an impairment of Stat1-dependent and Stat1-independent IFN-gamma signalling in macrophages of people with active tuberculosis, suggesting a different molecular regulation that could impact macrophage functionality and disease outcome.
Esquivel-Solís
H
H
Departamento de Microbiología y Parasitología, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Quiñones-Falconi
F
F
Zarain-Herzberg
A
A
Amieva-Fernández
R I
RI
López-Vidal
Y
Y
D000328:Adult; D015153:Blotting, Western / Q000379:methods; D016022:Case-Control Studies; D002467:Cell Nucleus / Q000737:chemistry / Q000378:metabolism; D003114:Colony-Forming Units Assay; D024202:Electrophoretic Mobility Shift Assay; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology* / Q000494:pharmacology; D016753:Interleukin-10 / Q000032:analysis / Q000276:immunology; D048031:JNK Mitogen-Activated Protein Kinases / Q000032:analysis / Q000378:metabolism*; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism; D008875:Middle Aged; D009169:Mycobacterium tuberculosis; D009569:Nitric Oxide / Q000032:analysis; D011994:Recombinant Proteins; D050794:STAT1 Transcription Factor / Q000032:analysis / Q000378:metabolism*; D050799:STAT5 Transcription Factor; D018709:Statistics, Nonparametric; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology* / Q000378:metabolism / Q000635:transmission; D025521:Tumor Suppressor Proteins; D055815:Young Adult
D011994:Recombinant Proteins; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D050799:STAT5 Transcription Factor; C494092:STAT5A protein, human; D016212:Transforming Growth Factor beta; D025521:Tumor Suppressor Proteins; D016753:Interleukin-10; D009569:Nitric Oxide; D007371:Interferon-gamma; D048031:JNK Mitogen-Activated Protein Kinases